| I. COMMENCED TRADING IN NOVEMBER | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M)% |
| INITIAL OFFERINGS | ||||||||
| ARYx Therapeutics Inc. (ARYX)1 | 8/31/07 | 11/7/07 | 5S | $10 | 17.5 | Morgan Stanley & Co. CIBC World Markets Jefferies & Co. Inc. Leerink Swann & Co. |
$50 | $175 |
|
Medgenics Inc. (AIM:MEDG) |
11/29/07 | 11/29/07 | N/A | £0.1 ($0.21) |
104S | SVS Securities Blomfield Corp. Finance (adviser) |
£3.28 ($6.76) |
£10.4 ($21.1) |
|
Nanoshere Inc. (NSPH)2 |
8/13/07 | 11/1/07 | 7S | $14 | 21.1 | Credit Suisse Piper Jaffray Leerink Swann & Co. Allen & Co. LLC |
$98 | $147.7 |
| OVERALLOTMENTS | ||||||||
|
Genoptix Inc. (GXDX)3 |
8/1/07 | 11/5/07 | 0.75S | $17 | 16.35 | Lehman Brothers Banc of America Sec. Cowen and Co. |
$12.75 | $277.95 |
| Total: $167.51M | ||||||||
|
Number of IPOs in November: 3 Number of IPOs in 2007: 39 |
Average value of November IPOs: $55.84 Total raised in IPOs in 2007: $1,814.56M |
|||||||
| Average value of IPOs in 2007: $46.53M | ||||||||
| FOLLOW-ON OFFERINGS | ||||||||
| Arena Pharmaceuticals Inc. (ARNA)4 | 10/22/07 | 11/2/07 | 11S | $9.91 | 72.2 | CIBC World Markets UBS Investment Bank (co-lead) |
$109.01 | $715.5 |
| Biopure Corp. (BPUR)5 | 11/1/07 | 11/1/07 | 19.4S | $0.85 | 35.0 | Dawson James Sec. | $16.5 | $29.75 |
| Total: $125.51M | ||||||||
|
Number of follow-on offerings in November: 2 Number of follow-on offerings in 2007: 49 |
Average value of November follow-ons: $62.76M Total raised in follow-ons in 2007: $2,855.49M |
|||||||
| Average value of follow-ons in 2007: $58.28M | ||||||||
| Notes: | ||||||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. AIM = Alternative Investment Market on the London Stock Exchange. 1 ARYx's overallotment option: 750,000 shares. 2 Nanosphere's overallotment option: 1.05M shares. 3 Genoptix's exercised overallotment option brings the total raised to $85.9M. 4 Arena's overallotment option: 1.65M shares. 5 Biopure's offering includes the overallotment option. Each new share was accompanied by a five-year warrant to buy one additional share at an exercise price of $1.06. | ||||||||
| II. FILED AND PENDING | ||||||
| Company (Symbol/Proposed Symbol)#* | Date Filed | Shares/Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) |
| INITIAL OFFERINGS | ||||||
| Aegerion Pharmaceuticals Inc. (AEGR) | 11/21/07 | N/A | N/A | N/A | Piper Jaffray Thomas Weisel Partners (co-lead) Lazard Capital Markets Collins Stewart LLC |
$86 |
| Anacor Pharmaceuticals Inc. (ANAC) | 8/31/07 | N/A | N/A | N/A | Morgan Stanley & Co. Inc. Cowen & Co. LLC (co-lead) Pacific Growth Equities LLC Needham & Co. LLC |
$57.5 |
| Archemix Corp. (ARCH) | 7/25/07 | N/A | N/A | N/A | Banc of America Securities Bear, Stearns & Co. Inc. Cowen and Co. |
$69 |
| Bioheart Inc. (BHRT) | 2/13/07 | 3.575S | $14-$16 | 16.9 | BMO Capital Markets Corp. Janney Montgomery Scott (co-lead) Merriman Curhan Ford & Co. |
$53.6 |
| Biolex Inc. (BLEX) | 8/14/07 | N/A | N/A | N/A | Lehman Brothers Inc. Deutsche Bank Securities (co-lead) Leerink Swann & Co. Inc. |
$70 |
| Chemocentryx Inc. (CCXI) | 11/12/07 | N/A | N/A | N/A | Credit Suisse Securities LLC Cowen and Co. Leerink Swann Lazard Capital Markets |
$57.5 |
| Elixir Pharmaceuticals Inc. (ELXR) | 9/24/07 | N/A | N/A | 143.5 | Credit Suisse Securities LLC Pacific Growth Equities Leerink Swann LLC |
$86 |
| Insys Therapeutics Inc. (INRX) | 8/20/07 | N/A | N/A | N/A | Banc of America Securities UBS Investment Bank (co-lead) JMP Securities Natixis Bleichroeder |
$86.25 |
| Light Sciences Oncology Inc. (LSON) | 4/21/06 | 5.25S | $14-$16 | 18.5 | Cowen & Co. Wachovia Securities (co-lead) Jefferies & Co. Thomas Weisel Partners |
$78.75 |
| Merrion Pharmaceuticals Ltd. (MERR) | 4/3/07 | 4S | $6-$7 | 15 | Punk, Ziegel & Co. Goodbody Stockbrokers Stanford Group Co. |
$26 |
| MonoSol Rx Inc. (MSRX) | 5/14/07 | 4S | $16-$18 | N/A | Cowen and Co. CIBC World Markets Susquehanna Financial |
$68 |
| NovaBay Pharmaceuticals Inc. (AMEX:NBY; TSX:NBY) | 2/15/07 | 5S | $4-$6 | 21.1 | Dundee Securities Desjardins Sec. International Blackmont Capital Dawson James Sec. |
$25 |
| Peplin Inc. (PLIN) | 8/10/07 | N/A | N/A | N/A | Merrill Lynch & Co. Cowen & Co. LLC Thomas Weisel Partners Leerink Swann & Co Merrill Lynch International Wilson HTM |
$75 |
| Precision Therapeutics Inc. (PRCN) | 8/24/07 | N/A | N/A | N/A | JP Morgan Piper Jaffray (co-lead) JMP Securities |
$80.5 |
| RXi Pharmaceuticals Corp. (RXIP; unit of CytRx Corp.) | 10/30/07 | 10.8S | N/A | N/A | N/A | N/A |
| Talecris Biothera-peutics Holdings Corp. (TLCR) | 7/30/07 | N/A | N/A | N/A | Morgan Stanley Goldman Sachs & Co. J.P. Morgan |
$1B |
| XDx Inc. (XDXI) | 10/24/07 | N/A | N/A | N/A | J.P. Morgan Securities Inc. Morgan Stanley & Co. (co-lead) Piper Jaffray & Co. JMP Securities LLC |
$86.3 |
| FOLLOW-ON OFFERINGS | ||||||
| Bioxel Pharma Inc. (Canada; CDNX:BIP) | 7/9/07 | N/A | N/A | N/A | Paradigm Capital Laurentian Bank Sec. |
N/A |
| Chemokine Therapeutics Corp. (Canada; TSX:CTI; OTC BB: CHKT) | 5/30/07 | N/A | N/A | N/A | GMP Securities | $25 |
| WITHDRAWN AND POSTPONED | ||||||
| Company (Symbol)# | Date Filed/Date Pulled | Shares/Units (M) | Price Range | Shares Out (M) @ | Lead, Other Underwriters | Value (M) |
|
MediciNova Inc. (MNOV)1 |
10/25/07 11/9/07 |
6S | $6.10 | N/A | Pacific Growth Equities HSBC Punk Ziegel & Co. Rodman & Renshaw |
$36.6 |
| Reliant Pharmaceuticals Inc. (NYSE:RRX)2 | 8/10/07 11/26/07 |
11.7S | $25-$27 | N/A | Goldman, Sachs & Co. Merrill Lynch & Co. (co-lead) Bank of America Securities Lazard Capital Markets |
$304.2 |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. * Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing. N/A = Not available, applicable or reported. AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. 1 MediciNova withdrew its offering due to general market conditions and unusual trading activity in its stock. 2 Reliant's IPO was withdrawn after GlaxoSmithKline plc made an offer to buy the company for $1.65 billion. | ||||||